GLP-1 Medications: Approved Uses, Side Effects, and Long-Term Considerations

GLP-1 agonists are currently approved by regulatory authorities for three medical conditions: type 2 diabetes, obesity, and reduction of heart attack and stroke risk. These medications include both injectable and oral formulations, with dosing frequencies ranging from daily to weekly.

Types of GLP-1 Agonists and Their Approved Uses

The brand-name GLP-1 medications and their corresponding generic names appear in a comparative table that lists each drug’s approved indications, formulation type, and dosing schedule. Wegovy (semaglutide) is approved for weight management and cardiovascular risk reduction, available as both a weekly injection and a daily pill. Foundayo (orforglipron), approved solely for weight management, is administered orally once per day. Zepbound (tirzepatide) and Saxenda (liraglutide) are injectable agents indicated for weight management, delivered weekly and daily respectively. Ozempic (semaglutide), Rybelsus (semaglutide), Mounjaro (tirzepatide), Victoza (liraglutide), and Trulicity (dulaglutide) are all approved for type 2 diabetes treatment; Ozempic and Trulicity are weekly injections, Rybelsus and Victoza are daily, and Mounjaro is weekly.

Long-Term Safety and Weight Regain Evidence

A 2022 study found that weight regain is likely following discontinuation of GLP-1 agonist therapy. Research on long-term effects remains limited. Healthcare professionals recommend pairing these medications with sustained dietary and lifestyle modifications. Ongoing guidance from a doctor or registered dietitian supports long-term weight management goals.

Eligibility and Clinical Guidance

Prescription of GLP-1 agonists requires evaluation by a doctor or other qualified healthcare professional. Eligibility depends on individual health concerns and goals, particularly in the context of type 2 diabetes, obesity, or cardiovascular disease. These drugs are not standalone interventions and must be used alongside diet changes and regular physical activity.

Documented Side Effects and Risks

Common side effects associated with GLP-1 agonists include vomiting, stomach pain, fatigue, constipation, diarrhea, and mood changes. Less frequent but more severe adverse events include allergic reaction (anaphylaxis), acute pancreatitis, acute cholelithiasis (gallstones), acute kidney injury, diabetic retinopathy in people with type 2 diabetes, changes in heart rate, suicidal behavior or ideation, and risk of thyroid C-cell tumors. Patients are advised to maintain regular contact with a healthcare provider and discuss any concerns about potential side effects before initiating or continuing treatment.

Muscle, Bone, and Exercise Interactions

Rapid weight loss induced by GLP-1 agonists leads to loss of both fat and lean mass—including muscle and bone density. Muscle contributes significantly to resting metabolic rate. Clinical studies indicate that 15% to 40% of total weight lost during GLP-1 therapy consists of lean mass. Strength training and other forms of exercise help preserve muscle while supporting fat loss. A 2024 analysis of a randomized clinical trial showed that individuals using liraglutide without exercise experienced decreased bone mineral density in the hips and spine, whereas those combining liraglutide with regular physical activity achieved optimal weight loss while maintaining bone density. Additional benefits of exercise—unavailable through GLP-1 therapy alone—include improved heart and lung function, enhanced mood, better sleep, and increased energy levels.

Off-Label Use and Individualized Care

Mounjaro is used off-label for weight loss and long-term weight management when combined with a balanced diet and exercise. The onset of effect and degree of weight loss vary among individuals. Patients should consult their doctor to understand expected timelines for results and to establish safe, personalized weight-loss targets based on their specific health profile.